Santhera Pharmaceuticals Holding Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Santhera Pharmaceuticals Holding wird ein jährliches Gewinn- und Umsatzwachstum von 35.4% bzw. 26.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 31.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 48.6% betragen.

Wichtige Informationen

35.4%

Wachstumsrate der Gewinne

31.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.7%
Wachstumsrate der Einnahmen	26.8%
Zukünftige Eigenkapitalrendite	48.6%
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Jun 26

Gewinn- und Umsatzwachstumsprognosen

SWX:SANN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CHF Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	135	53	61	61	1
12/31/2025	48	-10	-6	-6	2
12/31/2024	24	-35	-32	-32	2
6/30/2024	114	63	24	47	N/A
3/31/2024	109	59	24	47	N/A
12/31/2023	103	55	24	47	N/A
9/30/2023	54	-5	-7	7	N/A
6/30/2023	5	-65	-37	-33	N/A
3/31/2023	6	-68	-35	-32	N/A
12/31/2022	7	-71	-34	-30	N/A
9/30/2022	4	-68	-32	-30	N/A
6/30/2022	0	-65	-31	-31	N/A
3/31/2022	-1	-60	-34	-34	N/A
12/31/2021	-2	-56	-37	-37	N/A
9/30/2021	5	-56	-40	-40	N/A
6/30/2021	12	-56	-42	-42	N/A
3/31/2021	13	-62	-43	-43	N/A
12/31/2020	15	-68	-44	-44	N/A
9/30/2020	40	-46	-20	-20	N/A
6/30/2020	65	-24	3	3	N/A
3/31/2020	70	-21	3	3	N/A
12/31/2019	75	-19	2	3	N/A
9/30/2019	55	-37	-34	-14	N/A
6/30/2019	34	-54	-56	-36	N/A
3/31/2019	33	-54	-58	-37	N/A
12/31/2018	32	-54	-60	-38	N/A
9/30/2018	30	-58	-43	-41	N/A
6/30/2018	28	-56	-45	-42	N/A
3/31/2018	26	-54	N/A	-41	N/A
12/31/2017	23	-52	N/A	-40	N/A
9/30/2017	22	-42	N/A	-39	N/A
6/30/2017	23	-40	N/A	-33	N/A
3/31/2017	21	-38	N/A	-30	N/A
12/31/2016	19	-35	N/A	-27	N/A
9/30/2016	15	-21	N/A	-28	N/A
6/30/2016	10	-6	N/A	-29	N/A
3/31/2016	7	0	N/A	-25	N/A
12/31/2015	4	6	N/A	-22	N/A
9/30/2015	4	-3	N/A	-17	N/A
6/30/2015	3	-11	N/A	-11	N/A
3/31/2015	3	-10	N/A	-8	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	2	-7	N/A	-6	N/A
6/30/2014	1	-6	N/A	-5	N/A
3/31/2014	1	-6	N/A	-6	N/A
12/31/2013	1	-6	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SANNDas prognostizierte Gewinnwachstum (35.4% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: SANNDie Erträge des Unternehmens (35.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (11.3% pro Jahr).

Hohe Wachstumserträge: SANNEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: SANNDie Einnahmen des Unternehmens (26.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (4.2% pro Jahr).

Hohe Wachstumseinnahmen: SANNDie Einnahmen des Unternehmens (26.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SANNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (48.6%).

Santhera Pharmaceuticals Holding Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2024

Price target increased to CHF7.00

Forecast to breakeven in 2024

Price target decreased to CHF4.75

Consensus revenue estimates increase to CHF16.8m

Recent updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

New minor risk - Market cap size

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Price target increased to CHF7.00

Forecast to breakeven in 2024

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

Price target decreased to CHF4.75

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Consensus revenue estimates increase to CHF16.8m

Price target increased to CHF6.23

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company

Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2020 Final Results on Apr 27, 2021

New 90-day high: CHF3.20

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development

New 90-day low: CHF3.29

Analysts increase EPS estimates to -CHF3.25

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone